CA2094266A1 - Formulations - Google Patents

Formulations

Info

Publication number
CA2094266A1
CA2094266A1 CA 2094266 CA2094266A CA2094266A1 CA 2094266 A1 CA2094266 A1 CA 2094266A1 CA 2094266 CA2094266 CA 2094266 CA 2094266 A CA2094266 A CA 2094266A CA 2094266 A1 CA2094266 A1 CA 2094266A1
Authority
CA
Canada
Prior art keywords
beclomethasone
dipropionate
aerosol formulations
heptafluoropropane
tetrafluoroethane
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA 2094266
Other languages
English (en)
Other versions
CA2094266C (fr
Inventor
Robert K. Schultz
David W. Schultz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
3M Co
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24400688&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2094266(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Individual filed Critical Individual
Publication of CA2094266A1 publication Critical patent/CA2094266A1/fr
Application granted granted Critical
Publication of CA2094266C publication Critical patent/CA2094266C/fr
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A61K9/124—Aerosols; Foams characterised by the propellant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Otolaryngology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Formulations d'aérosol de solution pharmaceutique comprenant béclométhasone 17,21 dipropionate, éthanol ainsi qu'un propulseur choisi dans le groupe constitué de 1,1,1,2-tétrafluoroéthane, 1,1,1,2,3,3,3-heptafluoropropane, ainsi qu'un mélange de ceux-ci.
CA002094266A 1990-10-18 1991-10-09 Formulations Expired - Lifetime CA2094266C (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US59969490A 1990-10-18 1990-10-18
US599,694 1990-10-18
PCT/US1991/007574 WO1992006675A1 (fr) 1990-10-18 1991-10-09 Formulation d'aerosol contenant du beclomethasone 17,21 dipropionate

Publications (2)

Publication Number Publication Date
CA2094266A1 true CA2094266A1 (fr) 1992-04-19
CA2094266C CA2094266C (fr) 1999-06-01

Family

ID=24400688

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002094266A Expired - Lifetime CA2094266C (fr) 1990-10-18 1991-10-09 Formulations

Country Status (12)

Country Link
EP (1) EP0553298B1 (fr)
JP (2) JP2769925B2 (fr)
AT (1) ATE114112T1 (fr)
AU (1) AU658854B2 (fr)
BR (1) BR1100339A (fr)
CA (1) CA2094266C (fr)
DE (1) DE69105212T2 (fr)
DK (1) DK0553298T3 (fr)
ES (1) ES2064160T3 (fr)
HK (1) HK130397A (fr)
NZ (1) NZ240237A (fr)
WO (1) WO1992006675A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7220403B2 (en) 1999-09-11 2007-05-22 Glaxo Group Limited Pharmaceutical formulation of fluticasone propionate

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8828477D0 (en) 1988-12-06 1989-01-05 Riker Laboratories Inc Medical aerosol formulations
DE4123663A1 (de) * 1991-07-17 1993-01-21 Schwabe Willmar Gmbh & Co Aerosol-zubereitung und verwendung eines treibmittels dafuer
US5674471A (en) * 1991-12-12 1997-10-07 Glaxo Group Limited Aerosol formulations containing P134a and salbutamol
US5744123A (en) * 1991-12-12 1998-04-28 Glaxo Group Limited Aerosol formulations containing P134a and particulate medicaments
CA2125666C (fr) 1991-12-12 2002-07-16 Rachel Ann Akehurst Medicaments
US5653962A (en) * 1991-12-12 1997-08-05 Glaxo Group Limited Aerosol formulations containing P134a and particulate medicaments
US5736124A (en) * 1991-12-12 1998-04-07 Glaxo Group Limited Aerosol formulations containing P134a and particulate medicament
US5658549A (en) * 1991-12-12 1997-08-19 Glaxo Group Limited Aerosol formulations containing propellant 134a and fluticasone propionate
IL104068A (en) 1991-12-12 1998-10-30 Glaxo Group Ltd Pharmaceutical preparations in a spray without surfactant containing 1, 1, 1, 2 tetrafluoroethane or 1,1,2,3,3 petafluor N propane as propellant
EP0616525B1 (fr) * 1991-12-12 1995-09-27 Glaxo Group Limited Formulation d'aerosol pharmaceutique
US5916540A (en) 1994-10-24 1999-06-29 Glaxo Group Limited Aerosol formulations containing P134A and/or P227 and particulate medicament
US7101534B1 (en) 1991-12-18 2006-09-05 3M Innovative Properties Company Suspension aerosol formulations
GB9202519D0 (en) * 1992-02-06 1992-03-25 Glaxo Group Ltd Medicaments
MX9304585A (es) * 1992-07-31 1994-03-31 Glaxo Group Ltd Formulacion farmaceutica en aerosol, lata adecuada para liberar la formulacion e inhalador de dosis dosificada que comprende la lata.
US5833950A (en) * 1992-07-31 1998-11-10 Glaxo Group Limited Aerosol formulations containing beclomethasone dipropionate-1, 1, 1, 2-tetrafluoroethane solvate
US5593661A (en) * 1993-03-29 1997-01-14 Henry; Richard A. Lidocaine aerosol anaesthetic
NZ276637A (en) * 1993-12-20 1997-07-27 Minnesota Mining & Mfg Aerosol containing flunisolide, ethanol, and tetrafluoroethane and/or heptafluoropropane propellant
PE44995A1 (es) * 1994-01-27 1995-12-18 Schering Corp Furoato de mometasona para el tratamiento de las enfermedades pulmonares y de las vias respiratorias
US5653961A (en) * 1995-03-31 1997-08-05 Minnesota Mining And Manufacturing Company Butixocort aerosol formulations in hydrofluorocarbon propellant
US5874481A (en) * 1995-06-07 1999-02-23 Alliance Pharmaceutical Corp. Fluorochemical solutions for the delivery of lipophilic pharmaceutical agents
DK0835098T3 (da) 1995-06-27 2002-10-07 Boehringer Ingelheim Pharma Stabilt lægemiddelpræparat til frembringlese af drivgasfrie aerosoler
DE19616573C2 (de) 1996-04-25 1999-03-04 Pari Gmbh Verwendung unterkritischer Treibmittelmischungen und Aerosole für die Mikronisierung von Arzneimitteln mit Hilfe dichter Gase
GB9616237D0 (en) * 1996-08-01 1996-09-11 Norton Healthcare Ltd Aerosol formulations
JPH1067655A (ja) * 1996-08-23 1998-03-10 Nippon Hoechst Marion Roussel Kk 喘息治療用エアゾール剤
US6068832A (en) * 1996-08-29 2000-05-30 Schering Corporation Chlorofluorocarbon-free mometasone furoate aerosol formulations
ES2244008T3 (es) * 1996-12-04 2005-12-01 Link Products Limited Composiciones farmaceuticas y dispositivos para su administracion.
US6120752A (en) * 1997-05-21 2000-09-19 3M Innovative Properties Company Medicinal aerosol products containing formulations of ciclesonide and related steroids
GB2326334A (en) † 1997-06-13 1998-12-23 Chiesi Farma Spa Pharmaceutical aerosol compositions
US20010031244A1 (en) 1997-06-13 2001-10-18 Chiesi Farmaceutici S.P.A. Pharmaceutical aerosol composition
US6309623B1 (en) 1997-09-29 2001-10-30 Inhale Therapeutic Systems, Inc. Stabilized preparations for use in metered dose inhalers
US20060165606A1 (en) 1997-09-29 2006-07-27 Nektar Therapeutics Pulmonary delivery particles comprising water insoluble or crystalline active agents
US6565885B1 (en) 1997-09-29 2003-05-20 Inhale Therapeutic Systems, Inc. Methods of spray drying pharmaceutical compositions
US6433040B1 (en) 1997-09-29 2002-08-13 Inhale Therapeutic Systems, Inc. Stabilized bioactive preparations and methods of use
GB2332372B (en) * 1997-12-08 2002-08-14 Minnesota Mining & Mfg Pharmaceutical aerosol compositions
US6086376A (en) * 1998-01-30 2000-07-11 Rtp Pharma Inc. Dry aerosol suspension of phospholipid-stabilized drug microparticles in a hydrofluoroalkane propellant
GB9807232D0 (en) 1998-04-03 1998-06-03 Univ Cardiff Aerosol composition
US6264923B1 (en) 1998-05-13 2001-07-24 3M Innovative Properties Company Medicinal aerosol formulation of ciclesonide and related compounds
US6451285B2 (en) 1998-06-19 2002-09-17 Baker Norton Pharmaceuticals, Inc. Suspension aerosol formulations containing formoterol fumarate and a fluoroalkane propellant
IT1303788B1 (it) 1998-11-25 2001-02-23 Chiesi Farma Spa Formulazioni di aerosol medicinali.
US6004537A (en) * 1998-12-18 1999-12-21 Baker Norton Pharmaceuticals, Inc. Pharmaceutical solution aerosol formulations containing fluoroalkanes, budesonide and formoterol
US6290930B1 (en) 1998-12-18 2001-09-18 Baker Norton Pharmaceuticals, Inc. Pharmaceutical solution aerosol formulations containing fluoroalkanes and budesonide
US20030032632A1 (en) * 1999-12-24 2003-02-13 Crispps Leslie Alan Pharmaceutical aerosol formulation of salmeterol and fluticasone propionate
EP1280520B2 (fr) 2000-05-10 2018-03-21 Novartis AG Poudres a base de phospholipides permettant de distribuer un medicament
US7871598B1 (en) 2000-05-10 2011-01-18 Novartis Ag Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
US8404217B2 (en) 2000-05-10 2013-03-26 Novartis Ag Formulation for pulmonary administration of antifungal agents, and associated methods of manufacture and use
FR2813877B1 (fr) 2000-09-11 2002-12-06 Cezus Cie Europ Du Zirconium Procede de separation de metaux tels que le zirconium et l'hafnium
GB0208742D0 (en) 2002-04-17 2002-05-29 Bradford Particle Design Ltd Particulate materials
TWI324518B (en) 2001-12-19 2010-05-11 Nektar Therapeutics Pulmonary delivery of aminoglycosides
EP1340503A1 (fr) * 2002-03-01 2003-09-03 CHIESI FARMACEUTICI S.p.A. Formule d'une solution pour aerosol contenant des dérivés d'esters de 3,17 estratrien pour administration pulmonale
AUPS317302A0 (en) * 2002-06-25 2002-07-18 Drug Delivery Solutions Pty Ltd Metastable pharmaceutical compositions
KR20050045946A (ko) 2002-06-25 2005-05-17 애크럭스 디디에스 피티와이 리미티드 비정질 약학적 조성물을 이용한 경피전달속도의 제어
EP1635845A1 (fr) 2003-06-13 2006-03-22 ALTANA Pharma AG Combination de formoterol et ciclesonide
EP1670482B2 (fr) 2003-09-16 2022-06-29 Covis Pharma B.V. Utilisation de ciclesonide dans le traitement de maladies respiratoires
WO2008097664A1 (fr) 2007-02-11 2008-08-14 Map Pharmaceuticals, Inc. Procédé d'administration thérapeutique de dhe pour procurer un soulagement rapide de la migraine tout en minimisant le profil des effets secondaires
US8652443B2 (en) 2008-02-14 2014-02-18 Precision Dermatology, Inc. Foamable microemulsion compositions for topical administration
AR079451A1 (es) 2009-12-18 2012-01-25 Nycomed Gmbh Compuestos 3,4,4a,10b-tetrahidro-1h-tiopirano[4,3-c]isoquinolina
CN103282070B (zh) 2010-10-12 2016-08-10 艾瓦克斯医药爱尔兰公司 鼻喷装置
JP2014519519A (ja) 2011-06-15 2014-08-14 タケダ ゲゼルシャフト ミット ベシュレンクテル ハフツング 新規３，４，４ａ，１０ｂ−テトラヒドロ−１Ｈ−チオピラノ［４，３−ｃ］イソキノリン化合物
BR112013031791A2 (pt) 2011-06-17 2017-01-31 Takeda Gmbh derivados de ftalazinona-pirrolopirimidinacarboxamida
MX2014001940A (es) 2011-08-18 2014-03-27 Takeda Gmbh Producto farmaceutico de aerosol para administracion por inhalacion oral o nasal.
BR112014006459A2 (pt) * 2011-09-20 2017-03-28 Sergeants Pet Care Products Inc composições de interomone e seu uso para modificar o comportamento nas diferentes espécies de vertebrados
US9480688B2 (en) 2011-09-20 2016-11-01 Sergeant's Pet Care Products, Inc. Pheromone compositions and their use to modify behavior in different vertebrate species
WO2018069210A1 (fr) 2016-10-10 2018-04-19 Takeda Gmbh Tétrahydrofuro [3,4-c] isoquinolines en tant qu'inhibiteurs de pde4
US20200268706A1 (en) * 2017-02-27 2020-08-27 Gregory LEVITIN Combination of furosemide and steroids and application system therefor

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8432063D0 (en) * 1984-12-19 1985-01-30 Riker Laboratories Inc Physically modified steroids
DE4003270A1 (de) * 1990-02-03 1991-08-08 Boehringer Ingelheim Kg Neue treibgase und ihre verwendung in arzneimittelzubereitungen
IL97065A (en) * 1990-02-02 1994-01-25 Fisons Plc Repellent preparations for aerosol
DE4003272A1 (de) * 1990-02-03 1991-08-08 Boehringer Ingelheim Kg Neue treibgasmischungen und ihre verwendung in arzneimittelzubereitungen

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7220403B2 (en) 1999-09-11 2007-05-22 Glaxo Group Limited Pharmaceutical formulation of fluticasone propionate

Also Published As

Publication number Publication date
NZ240237A (en) 1994-06-27
EP0553298B1 (fr) 1994-11-17
DE69105212D1 (de) 1994-12-22
DK0553298T3 (da) 1995-04-18
AU658854B2 (en) 1995-05-04
JP2769925B2 (ja) 1998-06-25
AU9087391A (en) 1992-05-20
HK130397A (en) 1997-09-19
EP0553298A1 (fr) 1993-08-04
JPH10182467A (ja) 1998-07-07
BR1100339A (pt) 2000-07-18
ES2064160T3 (es) 1995-01-16
WO1992006675A1 (fr) 1992-04-30
CA2094266C (fr) 1999-06-01
JPH06501710A (ja) 1994-02-24
DE69105212T2 (de) 1995-03-23
ATE114112T1 (de) 1994-12-15

Similar Documents

Publication Publication Date Title
CA2094266A1 (fr) Formulations
CA2178473A1 (fr) Compositions d'aerosols a base de flunisolide
EP1277467A3 (fr) Formulations d' aérosols sans chlorofluorohydrocarbures
ZA924164B (en) Non-chlorofluorocarbon aerosol formulations
AU709052C (en) Suspension aerosol formulations
CA2381329A1 (fr) Medicaments
AU3038197A (en) Aerosol formulations
HK1009588A1 (en) Pharmaceutical aerosol formulations comprising beclomethasone dipropionate
AU5306486A (en) Drug-containing chlorofluorocarbon aerosol propellent formulations
GB2332372B (en) Pharmaceutical aerosol compositions
AU6882796A (en) Pharmaceutical compositions and devices for their administration
AU6326094A (en) New medicament aerosol formulation based on fusafungine, a process for its preparation and pharmaceutical compositions containing it
MX9707238A (es) Formulaciones en aerosol de butixocort.
CA2141039A1 (fr) Formulations d'aerosol exemptes de surfactif, renfermant du dipropionate de beclomethasone

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry